evaluate the pharmaceuticals company byetta on glp-1 medications comparison Drug in Diabetes and Obesity Treatment Battle of GLP-1 delivery technologies

In a PubPeer comment on the retraction, sleuth Alexander Magazinov said the imputation as described in the note is way more benign than the one described in the Retraction Watch blog post

In diesem Jahr ging es unter anderem darum, was eine Senkung des LDL-Cholesterins (LDL-C) fr einen Typ-1-Diabetiker bringt, welche Indikationen fr Lipidsenker in diesem Zusammenhang relevant sind und was an der Befrchtung dran ist, dass Statine das Diabetesrisiko erhhen knnen

Cell Death Dis (2022) 13(8):734

We then evaluate the limited treatment options currently available for general PACS and its neurological manifestations, emphasizing the unmet clinical needs in this area